



Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.
(OTC BB: BPTH)

Corporate Profile
April 2010

Sector: Biotech
Industry: Healthcare

Bio-Path Holdings, Inc
3293 Harrison Boulevard
Suite 220
Ogden, UT 84403
TEL: (801) 580 2326
www.biopathholdings.com

Bio-Path Holdings, Inc. (BPTH) is engaged in the business of facilitating the development of novel cancer therapeutics. The lead drugs are in the field of RNAi with a neutral lipid delivery technology for antisense and siRNA therapeutics. The Company has acquired three licenses from The University of Texas M. D. Anderson Cancer Center. Bio-Path will fund clinical development to advance these technologies through proof of concept, and then finalize a strategic plan for commercialization. In March of 2010, Bio-Path received IND approval from the FDA to commence a Phase I clinical trial in its lead drug candidate. For more information please visit www.biopathholdings.com.


Investment Highlights

- ◆ The Company is developing a revolutionary, patented, neutral lipid drug delivery system with two drug candidates ready for the clinic and a siRNA candidate within 12 months of entering clinical trials. The Company has received an IND from the FDA to commence a Phase I clinical trial in its lead drug candidate.
- ◆ The delivery system is inert in the body and has shown no evidence of toxicity to date.
- ◆ \$200 billion market potential for RNAi drugs.
- ◆ Bio-Path has three license agreements with The University of Texas M. D. Anderson Cancer Center, the world's leading cancer center.
- ◆ Bio-Path's neutral lipid drug delivery technology provides systemic distribution of nucleic acid drugs throughout the human body with a simple intravenous transfusion.
- ◆ The delivery technology applies to both single stranded (antisense) and double stranded (siRNA) nucleic acid drugs.
- ◆ The Company's existing portfolio of liposomal antisense and siRNA drug products provides confidence that the Company will have a strong current and future drug pipeline. Adding liposome targeting to these drugs will further enhance the pipeline.
- ◆ The management team and advisors at Bio-Path consist of pre-eminent scientists and leading clinicians who are proven drug developers.

Bio-Path Technology

Bio-Path's neutral lipid delivery technology provides systemic distribution of nucleic acid drugs throughout the human body with a simple intravenous transfusion. The delivery system is inert in the body and has shown no evidence of toxicity to date. The Company's delivery technology applies to both single stranded (antisense) and double stranded (siRNA) nucleic acid drugs. This technology has the potential to revolutionize the treatment of cancer and other diseases where the targets of disease are well characterized.

The neutral lipid delivery capability enables systemic delivery of nucleic acid drugs to diseased cells. This coupled with liposome tumor targeting technology will enable even greater efficiency delivering RNAi drugs to tumors, something no other technology can accomplish.



Antisense and siRNA

- ◆ Antisense and siRNA are single and double strand nucleic acid molecules that interfere with the process of producing proteins inside cells. They act by binding to the messenger RNA (mRNA) from the cell nucleus for the target protein, blocking the ability of the cell's machinery to produce the protein. Hence the process is called RNA interference (RNAi).
- ◆ Antisense and siRNA are molecules that can be synthesized chemically and introduced into cells
 - This creates enormous possibilities for using antisense and siRNA as drug products to treat major diseases including cancer.
- ◆ Introduction of an antisense or siRNA molecule specific to a target protein shuts down the cell's ability to produce that protein.
- ◆ Potential advantages of antisense and siRNA nucleic acid drug products include:
 - The ability to target virtually any disease-causing protein where the targets of the disease are well characterized
 - With antisense and siRNA therapeutics, it is possible to block the production of disease-causing proteins, which provides improved capability for disease control
 - Because antisense and siRNA are designed to target a specific disease-causing protein, the potential for other interactions that might cause toxicity is minimized.

Revenue Potential for a Bio-Path Drug?

BP-100-1.01 initially targets certain leukemia including: AML, ALL, MDS & CML, (also breast, colon & ovarian).
40,000 CML patients in the US alone.

Gleevec is the frontline treatment - \$25,000 per year per patient.
Because of Gleevec resistance, BP-100-1.01 expects to reach 20,000 patients. Produces annual revenue potential for AML, MDS, CLL & CML of \$500 million.

Gleevec generates \$2.2 Billion annually. The same 50% market assumption for BP-100-1.01 for all indications - \$1.1 billion a year.

Taxol is a broad anti-tumor drug - \$1.7 billion per year before off-patent.

Bio-Path's BP-100-1.02 drug targets these segments
- 50% is \$800 million a year.

Paraplatin is an ovarian and lung cancer treatment - \$900 million per year before off-patent.

Bio-Path's 1st siRNA drug BP-100.2.01 targets ovarian, colon, breast, thyroid, head and neck

Why Bio-Path?

The Company's drug delivery technology has the potential to revolutionize the treatment of cancer and other diseases where the targets of disease are well characterized.

Bio-Path currently has three drug candidates in its pipeline based on three licenses, with one lead candidate commencing a Phase I Clinical trial.

- The lead candidate is treating patients refractory or resistant to current treatments, and if Clinical success is achieved, the drug may receive an FDA "fast track" status to quickly move forward into an expanded Clinical Phase.
- The second candidate is ready for an IND submittal to the FDA, and with additional funding a third candidate will commence trials within a year of funding. The two lead drug candidates have large markets in the range of \$500 million to \$2 billion annually.
- The Company expects to add an additional 3-5 new drug candidates to its portfolio including the balance of the siRNA technology.

Bio-Path currently holds exclusive licenses to composition of matter patents that cover delivery of RNAi cancer drugs. These drugs provide efficient delivery of antisense and siRNA drugs substances to diseased cells. Also the liposome tumor targeting technology can be applied to the delivery liposomes thereby enhancing even further efficient delivery to tumors and other key organs in the body.

The method of delivery involves DOPC neutral lipids, a proven technology that is currently used with the marketed drug ABELCET (a liposomal antifungal drug developed by Bio-Path's founding researcher used to treat cancer patients with severe fungal infections).

The progress in developing antisense and siRNA therapeutics has been slowed by the lack of effective, non-toxic capability to deliver the drug substance to the diseased cells.

- **Bio-Path's delivery technology is the only delivery technology available to RNAi drug developers that can accomplish this without toxic side-effects.**

Management Team

Peter Nielsen - Co-founder, President and Chief Executive Officer and Chief Financial Officer, has been a director of the Company since its founding. He has developed a close working relationship over the last ten years with key individuals at M. D. Anderson and suppliers of the Company's lead drug product while coordinating pre-clinical and manufacturing development of Bio-Path's lead product. Mr. Nielsen has previously worked with several other biotech companies in a senior management capacity and as a Director, developing and executing on strategies for growth. Mr. Nielsen has a broad management background in senior management and has significant negotiating experience. He has engineering and MBA degrees from U.C. Berkeley.

Douglas P. Morris – Co-founder, Vice President of Corporate Development, Secretary and a Director, since 1993, Mr. Morris has been an officer and director of Celtic Investment, Inc., a financial services company that owns Celtic Bank, an FDIC insured industrial loan company chartered under the laws of the State of Utah. Since 1990, Mr. Morris owns and operates Hyacinth Resources, LLC ("Hyacinth"), a privately held business consulting firm. Mr. Morris has recently formed Sycamore Ventures, LLC, a privately-held consulting firm. Mr. Morris has a BA from Brigham Young University and a Masters degree from the University of Southern California.

This Company profile contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by our management.